Skip to content

To study the Bioequivalence of following oral administration of domestic lenalidomide capsules in multiple myeloma patients

To study the Bioequivalence of following oral administration of domestic lenalidomide capsules in multiple myeloma patients

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TTRCC-14004670
Enrollment
Unknown
Registered
2014-09-21
Start date
2014-03-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Interventions

Test Group:oral domestic produced lenalidomide capsule
Control:oral domestic produced lenalidomide capsule

Sponsors

West China Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria:? Men or postmenopausal women, aged 18 to 70 years old;? BMI=Body weight(kg)/Height2(m2),between 18 and 26;? ECOG performance status 60ml/min,AST, ALT = 80g/L,Absolute neutrophil count >*1.5*10 9/L,Platelets >= 80*10 9/L.Note:Ccr=(140-Age)×Body weight(kg)/[72×Scr(mg/dl)]?Ccr=[(140-Age)×Body weight(kg)]/[0.818×Scr(umol/L)]; Women by the results×0.85.? No smoking, no alcohol, and agreed to during the test ban smoking drinkers;? No parenting plan;? Aware of the potential teratogenic risk of drug, haematological toxicity (neutropenia and thrombocytopenia), caused by deep vein thrombosis and pulmonary embolism;? Not donate blood during the medication, wash-out period and after disabling the studied drug for at least 28 days;? Do not break, chew, or open the lenalidomide capsules;? In addition,for male subjects: have sex with the Women of childbearing potential to use condom during the medication, wash-out period and after disabling the studied drug for at least 28 days (it is no exception even if she have done vasectomy);? study entry and for the duration of study.

Exclusion criteria

Exclusion criteria: Exclusion Criteria: ? Any serious medical condition,laboratory abnormalities or mental illness can not participate this test; ? Pregnant or nursing; ? Any case of laboratory abnormalities,any risk for subjects and or will confuse the interpretation of the data; ? have significant heart disease activity within the previous 12 months; the angina have to be treated,have a history of poorly controlled hypertension (systolic blood pressure> 160, diastolic> 90mmHg); MI; class II-IV congestive heart failure according to New York Heart Association; Unstable angina. ? History of malignancy in addition to multiple myeloma, unless the patient has been cured cancer disease = 3 years,except for the following tumor diseases: Basal cell skin cancer; Cervical carcinoma in situ; Breast carcinoma in situ; Squamous cell carcinoma of the skin; ? Incidental histologic findings of prostate cancer (TNM staging of T1a or T1b); ? have history of drug allergy, allergic disease or allergic constitution; ? = 2 peripheral neuropathy (see Annex score 4.FACT/GOG-NTX); ? with DVT or PE within the previous 12 months; ? the patients have digestive diseases to drug absorption; ? the patients have urinary tract obstruction or difficulty urinating; ? the patient hypovolemia; ? subjects with HBsAg-positive,syphilis-positive, hepatitis C antibody-positive or HIV antibody-positive; ? participate any other drug test within the last 3 months; ? There is evidence to suggest drug abusers.

Countries

China

Contacts

Public ContactShen Qi
769824157@qq.com+86 13228212376

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026